VMD spotlights managed access for canine mast cell cancer care

CURRENT BRIEF VERSION: VMD Sciences said it helped a U.S. veterinary oncologist import an EMA-approved tyrosine kinase inhibitor that isn't available in the U.S. for an 8-year-old dog with metastatic mast cell cancer. In the January 30, 2026 announcement, the company said Dr. Seth Glasser of Garden State Veterinary Specialists in New Jersey used VMD’s managed access program to navigate documentation, customs clearance, and FDA inspection so the drug could be legally imported after standard options had failed. VMD identified the case as a low-grade subcutaneous mast cell tumor with lymph node metastasis, and said the treatment arrived within days. (static1.squarespace.com)

Why it matters: For veterinary professionals, the case highlights a practical route to therapies that may be approved abroad but remain unavailable domestically. That matters in canine mast cell disease, where treatment decisions can become limited once surgery, radiation, chemotherapy, or currently marketed U.S. options have been exhausted. It also lands as mast cell tumors get renewed attention across the care pathway: IDEXX recently said it plans to add canine mast cell tumor detection to its Cancer Dx Panel in mid-2026 and introduce in-clinic FNA cytology for mast cell tumors on the inVue Dx Cellular Analyzer, underscoring how both earlier detection and later-line treatment access are evolving. In the U.S., Palladia has long been an FDA-approved option for recurrent grade II or III cutaneous mast cell tumors, while other oncology tools, including Merck Animal Health’s gilvetmab, have expanded the specialist toolkit more recently. Supportive care is evolving too: the FDA recently renewed conditional approval of Jaguar Health’s Canalevia-CA1 for chemotherapy-induced diarrhea in dogs through December 21, 2026, giving oncologists another indication-specific option to help keep patients comfortable and on protocol. Managed access won't fit every case, but it may offer oncologists another path for select patients with advanced disease and a strong clinical rationale. (fda.gov)

What to watch: Watch for whether more specialty practices use managed access pathways for oncology drugs, and whether sponsors turn those one-off imports into broader managed entry or U.S. commercialization efforts. It will also be worth watching how newer mast cell tumor diagnostics and supportive-care tools change referral timing, case selection, and treatment continuity in oncology practice. (vmdsciences.com)